The role of drug timing and histoincompatibility barrier in prolongation of cardiac graft survival in mice treated with donor-specific blood and cyclophosphamide.
In the H-2-compatible donor-recipient combination (BALB/c----DBA/2), pretransplant donor-specific blood transfusion (DST) significantly prolonged graft survival. Concomitant use of immunosuppression by cyclophosphamide (CY) brought about potentiation of DST effect, resulting in long-term graft survival. In contrast, in the 'strong' H-2-incompatible combination (BALB/c----CBA/H) pretreatment of the recipients with donor-specific blood resulted in hyperacute graft rejection or in impairment of drug-induced immunosuppression when DST was used with a single dose of CY. In this model however, combination of DST with both pre- and posttransplant CY immunosuppression interacted beneficially to produce significant donor-specific prolongation of graft survival.
Lasek
W
W
Department of Transplantology, Institute of Biostructure, Medical School, Warsaw, Poland.
Jakóbisiak
M
M
Płodzisewska
M
M
Szczytnicki
W
W
Górecki
D
D
D000818:Animals; D001803:Blood Transfusion; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006085:Graft Survival / Q000187:drug effects*; D006183:H-2 Antigens / Q000276:immunology; D016027:Heart Transplantation; D051379:Mice; D008815:Mice, Inbred Strains; D014184:Transplantation, Homologous
D006183:H-2 Antigens; D003520:Cyclophosphamide